U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H9ClF3NO2
Molecular Weight 315.6754
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EFAVIRENZ

SMILES

C1CC1C#C[C@]2(c3cc(ccc3N=C(O)O2)Cl)C(F)(F)F

InChI

InChIKey=XPOQHMRABVBWPR-ZDUSSCGKSA-N
InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

CNS Activity

Originator

Merck
202
Curator's Comment:: # Merck & Co

Approval Year

1998
113
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
7728
 4.0 nM [EC50]
Inhibitor
7728
 26.1 µM [IC50]
Modulator
780
 52.0 µM [IC50]
Inhibitor
7728
 20.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8043
SUSTIVA

Approved Use

SUSTIVA is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection.

Launch Date

9.05904E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12.9 μM
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EFAVIRENZ plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.04 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EFAVIRENZ plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
184 μM × h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EFAVIRENZ plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
257.56 μM × h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EFAVIRENZ plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
40 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EFAVIRENZ plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EFAVIRENZ plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 g single, oral
Overdose
Dose: 3 g
Route: oral
Route: single
Dose: 3 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/23077707
unhealthy, 12 years
n = 1
Health Status: unhealthy
Condition: HIV infection
Age Group: 12 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/23077707
Sources:
https://pubmed.ncbi.nlm.nih.gov/23077707
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Co-administed with::
abacavir(300 mg q12h)
nelfinavir(1250 mg q12h)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11418896
unhealthy, 33 years
n = 1
Health Status: unhealthy
Condition: HIV infection
Age Group: 33 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/11418896
Disc. AE: Mania...
AEs leading to
discontinuation/dose reduction:
Mania (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11418896
25 mg/kg 1 times / day steady, oral
Highest studied dose
Dose: 25 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28483965
unhealthy, 33.9 months (range: 29.2–40.2 months)
n = 52
Health Status: unhealthy
Condition: HIV infection
Age Group: 33.9 months (range: 29.2–40.2 months)
Sex: M+F
Population Size: 52
Sources:
https://pubmed.ncbi.nlm.nih.gov/28483965
Sources:
https://pubmed.ncbi.nlm.nih.gov/28483965
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
unhealthy, 37.3 years
n = 67
Health Status: unhealthy
Condition: tuberculosis
Age Group: 37.3 years
Sex: M+F
Population Size: 67
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
Disc. AE: Hallucination, Dizziness...
AEs leading to
discontinuation/dose reduction:
Hallucination (1 patient)
Dizziness (1 patient)
Insomnia (1 patient)
Hepatotoxicity (1 patient)
Skin rash (1 patient)
Pruritus (1 patient)
Rash (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
AEs

AEs

AESignificanceDosePopulation
Mania 1 patient
Disc. AE
600 mg 1 times / day multiple, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Co-administed with::
abacavir(300 mg q12h)
nelfinavir(1250 mg q12h)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11418896
unhealthy, 33 years
n = 1
Health Status: unhealthy
Condition: HIV infection
Age Group: 33 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/11418896
Dizziness 1 patient
Disc. AE
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
unhealthy, 37.3 years
n = 67
Health Status: unhealthy
Condition: tuberculosis
Age Group: 37.3 years
Sex: M+F
Population Size: 67
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
Hallucination 1 patient
Disc. AE
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
unhealthy, 37.3 years
n = 67
Health Status: unhealthy
Condition: tuberculosis
Age Group: 37.3 years
Sex: M+F
Population Size: 67
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
Hepatotoxicity 1 patient
Disc. AE
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
unhealthy, 37.3 years
n = 67
Health Status: unhealthy
Condition: tuberculosis
Age Group: 37.3 years
Sex: M+F
Population Size: 67
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
Insomnia 1 patient
Disc. AE
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
unhealthy, 37.3 years
n = 67
Health Status: unhealthy
Condition: tuberculosis
Age Group: 37.3 years
Sex: M+F
Population Size: 67
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
Pruritus 1 patient
Disc. AE
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
unhealthy, 37.3 years
n = 67
Health Status: unhealthy
Condition: tuberculosis
Age Group: 37.3 years
Sex: M+F
Population Size: 67
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
Rash 1 patient
Disc. AE
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
unhealthy, 37.3 years
n = 67
Health Status: unhealthy
Condition: tuberculosis
Age Group: 37.3 years
Sex: M+F
Population Size: 67
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
Skin rash 1 patient
Disc. AE
800 mg 1 times / day steady, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
unhealthy, 37.3 years
n = 67
Health Status: unhealthy
Condition: tuberculosis
Age Group: 37.3 years
Sex: M+F
Population Size: 67
Sources:
https://pubmed.ncbi.nlm.nih.gov/30792988
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:119486
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:119486
ChemicalBook
CB7181559
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7181559
MolPort
MolPort-003-983-924
https://www.molport.com/shop/molecule-link/MolPort-003-983-924
ZINC
ZINC000002020233
http://zinc15.docking.org/substances/ZINC000002020233
eMolecules
2735350
https://www.emolecules.com/cgi-bin/more?vid=2735350
PubMed

PubMed

TitleDatePubMed
Antiretroviral therapy in pregnancy: a focus on safety.
2001
A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors.
2001
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
2001 Apr 15
A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.
2001 Apr 15
Antiretroviral rounds. When success is a pain.
2001 Aug
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
2001 Aug
Antiviral drugs: current state of the art.
2001 Aug
Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz.
2001 Aug 1
Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks.
2001 Aug 15
Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy.
2001 Aug 17
Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
2001 Aug 2
Solution structures and reactivities of the mixed aggregates derived from n-butyllithium and vicinal amino alkoxides.
2001 Aug 22
Antiretroviral therapy for previously treated patients.
2001 Aug 9
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
2001 Aug 9
Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
2001 Feb 1
Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach?
2001 Jan-Feb
Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases.
2001 Jan-Feb
Predictors of protease inhibitor-associated adverse events.
2001 Jul
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
2001 Jul 1
Manic syndrome associated with efavirenz overdose.
2001 Jul 15
Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors.
2001 Jul 23
Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz.
2001 Jul 27
Management of sudden psychiatric disorders related to efavirenz.
2001 Jul 6
Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis.
2001 Jul-Aug
In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
2001 Jun
Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.
2001 Jun
[Vertical trasmission of human immunodeficiency virus (HIV) and other sexually transmitted infections (STI)].
2001 Jun
Efavirenz plasma concentrations and efficiency.
2001 Jun 15
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
2001 Jun 15
Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA.
2001 Jun 6
Efavirenz-induced acute eosinophilic hepatitis.
2001 May
Efavirenz-induced photoallergic dermatitis in HIV.
2001 May 25
High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy.
2001 May 5
[Apropos of atypical melancholia with Sustiva (efavirenz)].
2001 May-Jun
[Drug interactions with antiretroviral agents].
2001 May-Jun
Other issues: penetration into sanctuary sites, immune reconstitution and NNRTI sequencing.
2001 Nov
Factors affecting adherence and convenience in antiretroviral therapy.
2001 Nov
Comparison of NNRTIs in antiretroviral-experienced patients.
2001 Nov
Comparison of NNRTIs in antiretroviral-naïve patients.
2001 Nov
The role of NNRTIs in antiretroviral combination therapy: an introduction.
2001 Nov
New developments in anti-HIV chemotherapy.
2001 Nov
The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors.
2001 Nov 30
Thiosugars. VIII. Preparation of new 4'-thio-L-lyxo pyrimidine nucleoside analogues.
2001 Sep
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.
2001 Sep
Efavirenz-induced psychosis.
2001 Sep 28
Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.
2001 Sep 28
Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
2001 Sep 28
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
2001 Sep 3
Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
2001 Sep 7
Switching from protease inhibitors to the non-nuke efavirenz.
2001 Spring
Patents

Patents

08378143
2
JP4676536B2
25
JP4708329B2
13
JP4738172B2
26

Sample Use Guides

In Vivo Use Guide
SUSTIVA should be taken orally once daily on an empty stomach, preferably at bedtime. • Recommended adult dose: 600 mg. • With voriconazole, increase voriconazole maintenance dose to 400 mg every 12 hours and decrease SUSTIVA dose to 300 mg once daily using the capsule formulation.
Route of Administration: Oral
In Vitro Use Guide
10 pM efavirenz completely inhibited 0.5 U HIV RT.
Name Type Language
EFAVIRENZ
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
EFAVIRENZ [USP MONOGRAPH]
Common Name English
SUSTIVA
Brand Name English
(S)-6-CHLORO-4-(CYCLOPROPYLETHYNYL)-1,4-DIHYDRO-4-(TRIFLUOROMETHYL)-2H-3,1-BENZOXAZIN-2-ONE
Systematic Name English
EFAVIRENZ [EMA EPAR]
Common Name English
NSC-742403
Code English
EFAVIRENZ [MI]
Common Name English
EFAVIRENZ [VANDF]
Common Name English
EFAVIRENZ [ORANGE BOOK]
Common Name English
EFAVIRENZ [WHO-IP]
Common Name English
EFAVIRENZ [WHO-DD]
Common Name English
EFAVIRENZUM [WHO-IP LATIN]
Common Name English
EFAVIRENZ [HSDB]
Common Name English
EFAVIRENZ [JAN]
Common Name English
VIRADAY
Brand Name English
EFAVIRENZ [INN]
Common Name English
TELURA COMPONENT EFAVIRENZ
Common Name English
STOCRIN
Brand Name English
EFAVIRENZ [USP-RS]
Common Name English
EFAVIRENZ TEVA
Brand Name English
EFV
Common Name English
EFAVIRENZ [MART.]
Common Name English
EFAVIRENZ COMPONENT OF ATRIPLA
Common Name English
ATRIPLA COMPONENT EFAVIRENZ
Common Name English
Classification Tree Code System Code
NDF-RT N0000009948
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
LIVERTOX 341
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
WHO-ATC J05AR11
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
NDF-RT N0000175460
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
EMA ASSESSMENT REPORTS SUSTIVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
EMA ASSESSMENT REPORTS ATRIPLA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
NDF-RT N0000175463
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (EFV/FTC/TEN)
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
WHO-VATC QJ05AR11
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
WHO-ATC J05AR06
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
WHO-VATC QJ05AR06
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.2
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
NCI_THESAURUS C97453
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
WHO-VATC QJ05AG03
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
WHO-ATC J05AG03
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
EMA ASSESSMENT REPORTS STOCRIN (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
EMA ASSESSMENT REPORTS EFAVIRENZ TEVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
Code System Code Type Description
NDF-RT
N0000182140
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
ChEMBL
CHEMBL223228
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
USP_CATALOG
1234103
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY USP-RS
EPA CompTox
154598-52-4
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
DRUG CENTRAL
989
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
EFAVIRENZ
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY Description: White to slightly pink powder.Solubility: Practically insoluble in water, freely soluble in methanol.Category. Antiretroviral (Non-nucleoside Reverse Transcriptase Inhibitor).Storage. Efavirenz should be kept in a well-closed container, protected from light.Additional information: Efavirenz may exhibit polymorphism.Requirements: Definition: Efavirenz contains not less than 97.0% and not more than 103.0% of C14H9ClF3NO2, calculated with reference to thedried substance.Manufacture: The production method is validated to ensure that the substance is the (4S)-enantiomer.
EVMPD
SUB06463MIG
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
PUBCHEM
64139
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
MESH
C098320
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
RXCUI
195085
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY RxNorm
NDF-RT
N0000182141
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
LACTMED
Efavirenz
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
MERCK INDEX
M4839
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY Merck Index
HSDB
7163
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
INN
7718
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
FDA UNII
JE6H2O27P8
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
NCI_THESAURUS
C29027
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
WIKIPEDIA
EFAVIRENZ
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
NDF-RT
N0000185504
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY Cytochrome P450 2C9 Inhibitors [MoA]
NDF-RT
N0000187064
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY Cytochrome P450 2B6 Inducers [MoA]
CAS
154598-52-4
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
DRUG BANK
DB00625
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY
NDF-RT
N0000190118
Created by admin on Fri Jun 25 21:38:46 UTC 2021 , Edited by admin on Fri Jun 25 21:38:46 UTC 2021
PRIMARY Cytochrome P450 3A Inducers [MoA]
ACTIVE MOIETY
Structure of EFAVIRENZ
METABOLITE (PARENT)
Structure of 7-HYDROXYEFAVIRENZ
METABOLITE ACTIVE (PARENT)
Structure of 8-HYDROXYEFAVIRENZ
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966